Intermediate ss-cDNA (red), Pol cDNA (orange), SD’ cDNA (green) and the final product FL DNA (purple) are shown. doi:10.1371/journal.pone.0051534.gRoles of the NC in HIV-1 11967625 and MuLV ReplicationsFigure 4. Quantitative analysis of the nucleic acid content of viral particles released from MuLV producer cells. (A) Quantitation of viral gRNA incorporated in wt or mutant viruses by RT-QPCR. Mock controls were get 1948-33-0 subtracted from assays. Error bars indicate SD from at least four independent experiments. (B) Viral DNA levels were determined by qPCR in the wt and mutant virions. DNA was extracted from same virion samples as those used before for gRNA quantitation. Error bars indicate SD from at least seven independent experiments. (C) There is no correlation between gRNA and viral DNA levels among the MuLV mutants. For comparative purpose, data obtained with HIV-1 virions deleted of the second ZF (DZF2) are given (left part) [26,38]. To facilitate the comparison, levels of viral gRNA and ss-cDNA were normalized to those measured in wt virions. doi:10.1371/journal.pone.0051534.gbetween the virions with a mutated NC, a defective PR (PR-) and the wt MuLV particles (Fig 4B). Previously, we showed that the alternatively spliced SD’ RNA, generated by usage of the SD’ and SA splicing sites (Fig 3), is specifically incorporated in wt MuLV and is reverse transcribed as efficiently as the unspliced gRNA [44]. Thus, the spliced SD’-cDNA would be a useful alternative for specific viral DNA quantitation without the requirement to remove the contaminant pRR88 cps. It was not possible to detect specific SD’ cDNA forms in neither wt nor NC-mutant viruses. Average levels of spliced SD’ cDNA measured in the DNA samples (36102 copies) were not significantly different from the background level measured with the mock control using culture supernatant collected from mock-transfected cells (see methods). The presence of MuLV cDNA (ss-cDNA and SD’ cDNA) in producer cells was examined as previously described [26]. In contrast to HIV-1, the viral cDNA was not found in cellular DNA samples (data not shown). These results are consistent with those on the virion viral DNA content and indicate the absence of active late RTion in MuLV producer cells (Fig 4B).Analysis of the coexpression of MuLV and HIV-MuLV and HIV-1 NCs have similar functions in assembly which is further highlighted by the production of chimeric MuLVHIV-1 VLPs. In addition, the HIV NC can recognize the MuLV RNA genome although less efficiently than the HIV-1 gRNA [12,45]. Based on these observations, we wanted to examine whether in the context of complete viruses, the expression of the DZF2 HIV-1 mutant, which produced DNA-containing particles,could confer late RTion activity to MuLV. HIV-1 DZF2 NC could recognize the MuLV gRNA, causing its reverse transcription as for the HIV-1 gRNA. To this end, MuLV was cotransfected with the wt or DZF2 HIV-1 molecular clone (pNL4-3). No HIV tracer was added to the supernatants during these assays. First, we examined the particles released by Western 26001275 immunoblotting with CASIN site anti-CA antibodies specific for MuLV or HIV-1 (Fig 5A). Surprisingly, MuLV production was impaired in presence of the DZF2 HIV-1 mutant, but not by the wt HIV-1. In contrast, DZF2 HIV-1 production remained unchanged with or without MuLV. Then, we analyzed the DNA content of the released particles. Examination of MuLV DNA in virion released when MuLV and DZF2 were coexpressed, showed a reduction of the intraviri.Intermediate ss-cDNA (red), Pol cDNA (orange), SD’ cDNA (green) and the final product FL DNA (purple) are shown. doi:10.1371/journal.pone.0051534.gRoles of the NC in HIV-1 11967625 and MuLV ReplicationsFigure 4. Quantitative analysis of the nucleic acid content of viral particles released from MuLV producer cells. (A) Quantitation of viral gRNA incorporated in wt or mutant viruses by RT-QPCR. Mock controls were subtracted from assays. Error bars indicate SD from at least four independent experiments. (B) Viral DNA levels were determined by qPCR in the wt and mutant virions. DNA was extracted from same virion samples as those used before for gRNA quantitation. Error bars indicate SD from at least seven independent experiments. (C) There is no correlation between gRNA and viral DNA levels among the MuLV mutants. For comparative purpose, data obtained with HIV-1 virions deleted of the second ZF (DZF2) are given (left part) [26,38]. To facilitate the comparison, levels of viral gRNA and ss-cDNA were normalized to those measured in wt virions. doi:10.1371/journal.pone.0051534.gbetween the virions with a mutated NC, a defective PR (PR-) and the wt MuLV particles (Fig 4B). Previously, we showed that the alternatively spliced SD’ RNA, generated by usage of the SD’ and SA splicing sites (Fig 3), is specifically incorporated in wt MuLV and is reverse transcribed as efficiently as the unspliced gRNA [44]. Thus, the spliced SD’-cDNA would be a useful alternative for specific viral DNA quantitation without the requirement to remove the contaminant pRR88 cps. It was not possible to detect specific SD’ cDNA forms in neither wt nor NC-mutant viruses. Average levels of spliced SD’ cDNA measured in the DNA samples (36102 copies) were not significantly different from the background level measured with the mock control using culture supernatant collected from mock-transfected cells (see methods). The presence of MuLV cDNA (ss-cDNA and SD’ cDNA) in producer cells was examined as previously described [26]. In contrast to HIV-1, the viral cDNA was not found in cellular DNA samples (data not shown). These results are consistent with those on the virion viral DNA content and indicate the absence of active late RTion in MuLV producer cells (Fig 4B).Analysis of the coexpression of MuLV and HIV-MuLV and HIV-1 NCs have similar functions in assembly which is further highlighted by the production of chimeric MuLVHIV-1 VLPs. In addition, the HIV NC can recognize the MuLV RNA genome although less efficiently than the HIV-1 gRNA [12,45]. Based on these observations, we wanted to examine whether in the context of complete viruses, the expression of the DZF2 HIV-1 mutant, which produced DNA-containing particles,could confer late RTion activity to MuLV. HIV-1 DZF2 NC could recognize the MuLV gRNA, causing its reverse transcription as for the HIV-1 gRNA. To this end, MuLV was cotransfected with the wt or DZF2 HIV-1 molecular clone (pNL4-3). No HIV tracer was added to the supernatants during these assays. First, we examined the particles released by Western 26001275 immunoblotting with anti-CA antibodies specific for MuLV or HIV-1 (Fig 5A). Surprisingly, MuLV production was impaired in presence of the DZF2 HIV-1 mutant, but not by the wt HIV-1. In contrast, DZF2 HIV-1 production remained unchanged with or without MuLV. Then, we analyzed the DNA content of the released particles. Examination of MuLV DNA in virion released when MuLV and DZF2 were coexpressed, showed a reduction of the intraviri.
Related Posts
And intragenic CG of intermediate CpG content, hence largely resembling the profile of 5mC. It
And intragenic CG of intermediate CpG content, hence largely resembling the profile of 5mC. It is
Ially noteworthy is the fact that sulfide removal by SOM also benefits cyanobacteria, for which
Ially noteworthy is the fact that sulfide removal by SOM also benefits cyanobacteria, for which higher concentrations of sulfide are toxic. Coordination of metabolisms may perhaps be facilitated by QS in this case. Inter-specific QS may perhaps ultimately be a key method in shaping the biofilm architecture. This is at present under investigation. 3. Experimental […]
Heal tube with controlled ventilation for the second phase Only remifentanil
Heal tube with controlled ventilation for the second phase Only remifentanil 1 ng mlAndersen 2010 [20]TIVA (propofol + remifentanil)Beez 2013 [21]TIVA (propofol + remifentanil)Bilotta 2014 [10]NABoetto 2015 [22]TCI-TIVA (propofol + Remifentanil)Cai 2013 [23]TCI-TIVA (propofol + Remifentanil)NKRocuronium 0.6mg kg-BISOesophageal nasopharyngeal catheter (controlled ventilation)Chacko 2013 [24]NAInitial: 50 g boluses of Relugolix biological activity fentanyl and propofol or […]